In this study, we have identified a subgroup of patients with lymph-node negative basal-like early-stage breast cancer with excellent outcomes, characterized by high tumor gene expression of CTLA4. Favorable outcomes are seen in patients treated with and without adjuvant chemotherapy. The gene discussed is CTLA4; the disease is breast carcinoma.